Metastatic pancreatic cancer: ASCO guideline update Guidelines

  


Authors: Sohal, D. P. S.; Kennedy, E. B.; Cinar, P.; Conroy, T.; Copur, M. S.; Crane, C. H.; Garrido-Laguna, I.; Lau, M. W.; Johnson, T.; Krishnamurthi, S.; Moravek, C.; O'Reilly, E. M.; Philip, P. A.; Pant, S.; Shah, M. A.; Sahai, V.; Uronis, H. E.; Zaidi, N.; Laheru, D.
Title: Metastatic pancreatic cancer: ASCO guideline update
Abstract: PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatmenteligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinalcancer- guidelines. Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
Journal Title: Journal of Clinical Oncology
Volume: 38
Issue: 27
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2020-09-20
Start Page: 3217
End Page: 3230
Language: English
DOI: 10.1200/jco.20.01364
PUBMED: 32755482
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092477609&doi=10.1200%2fJCO.20.01364&partnerID=40&md5=3141604199547602cc2e2c8d32fec7bf
Notes: Review -- Export Date: 2 November 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eileen O'Reilly
    780 O'Reilly
  2. Christopher Crane
    201 Crane
Related MSK Work